These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors. Coura BP; Dos Santos JN; Fonseca FP; Bernardes VF; de Aquino SN; Jorge Júnior J; Vargas PA; Romañach MJ; de Andrade BAB; Gomez RS; Gomes CC J Oral Pathol Med; 2021 Nov; 50(10):1067-1071. PubMed ID: 34549835 [TBL] [Abstract][Full Text] [Related]
10. Novel targets for the treatment of ameloblastoma. Heikinheimo K; Kurppa KJ; Elenius K J Dent Res; 2015 Feb; 94(2):237-40. PubMed ID: 25425580 [No Abstract] [Full Text] [Related]
11. Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies. Shi HA; Ng CWB; Kwa CT; Sim QXC Surgeon; 2021 Aug; 19(4):238-243. PubMed ID: 32712102 [TBL] [Abstract][Full Text] [Related]
12. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. You Z; Liu SP; Du J; Wu YH; Zhang SZ J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659 [TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. Ji Z; Mei FC; Xie J; Cheng X J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198 [TBL] [Abstract][Full Text] [Related]
14. High frequency of BRAF V600E mutations in ameloblastoma. Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844 [TBL] [Abstract][Full Text] [Related]
15. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168 [TBL] [Abstract][Full Text] [Related]
16. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422 [TBL] [Abstract][Full Text] [Related]
17. Ultra-frequent HRAS p.Q61R somatic mutation in canine acanthomatous ameloblastoma reveals pathogenic similarities with human ameloblastoma. Peralta S; McCleary-Wheeler AL; Duhamel GE; Heikinheimo K; Grenier JK Vet Comp Oncol; 2019 Sep; 17(3):439-445. PubMed ID: 31041834 [TBL] [Abstract][Full Text] [Related]
18. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas. Kumamoto H; Takahashi N; Ooya K J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485 [TBL] [Abstract][Full Text] [Related]
19. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma]. Yan XC; Sun LS; Dong ZW; You Z; Dong Q Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373 [TBL] [Abstract][Full Text] [Related]
20. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors. Bologna-Molina R; Ogawa I; Mosqueda-Taylor A; Takata T; Sánchez-Romero C; Villarroel-Dorrego M; Takeda Y; Mikami T Oral Dis; 2019 Mar; 25(2):481-487. PubMed ID: 30294831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]